Gilead Sciences Dirección

Dirección controles de criterios 3/4

El CEO de Gilead Sciences es Dan O'Day , nombrado en Mar 2019, tiene una permanencia de 4.5 años. compensación anual total es $21.62M, compuesta por 7.8% salario y 92.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de CHF26.58M. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 5.1 años, respectivamente.

Información clave

Dan O'Day

Chief Executive Officer (CEO)

US$21.6m

Compensación total

Porcentaje del salario del CEO	7.8%
Permanencia del CEO	4.5yrs
Participación del CEO	0.03%
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan O'Day en comparación con los beneficios de Gilead Sciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

Compensación vs. Mercado: La compensación total de Dan($USD21.62M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD4.74M).

Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.

CEO

Dan O'Day (59 yo)

4.5yrs

Permanencia

US$21,621,253

Compensación

Mr. Daniel P. O'Day, also known as Dan, serves as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019. He served as Member of Supervisory Board at Galapagos NV since October 22,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% CHF 26.6m
Andrew Dickinson	Executive VP & CFO	3.8yrs	US$8.40m	0.0088% CHF 7.6m
Deborah Telman	Executive VP of Corporate Affairs	1.1yrs	US$4.82m	0.00052% CHF 448.8k
Johanna Mercier	Chief Commercial Officer	4.2yrs	US$9.24m	0.0072% CHF 6.2m
Merdad Parsey	Chief Medical Officer	3.8yrs	US$9.04m	0.0056% CHF 4.9m
Sandra Patterson	Senior VP	less than a year	sin datos	0.0024% CHF 2.1m
Jacquie Ross	Vice President of Investor Relations	2.7yrs	sin datos	sin datos
Jyoti Mehra	Executive Vice President of Human Resources	4.1yrs	sin datos	sin datos
Michael Quigley	Senior Vice President of Research Biology	3.6yrs	sin datos	sin datos
Linda Higgins	Senior Vice President of Research	3.6yrs	sin datos	sin datos
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	sin datos	sin datos
Flavius Martin	Executive Vice President of Research	2.4yrs	sin datos	sin datos

3.6yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 000935700 se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% CHF 26.6m
Anthony Welters	Independent Director	2.9yrs	US$429.93k	0.00064% CHF 552.4k
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	sin datos
Jacqueline Barton	Independent Director	5.7yrs	US$414.88k	0.0018% CHF 1.5m
Eugene Schiff	Member of the Scientific Advisory Board	no data	sin datos	sin datos
John Mellors	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Francis Chisari	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Paul Klotman	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Kevin Lofton	Lead Independent Director	14.2yrs	US$489.93k	0.0074% CHF 6.4m
Kelly Kramer	Independent Director	7.1yrs	US$434.93k	0.00011% CHF 94.9k
Joel Huff	Chairperson of Scientific Advisory Board	no data	sin datos	sin datos
Grace Colon	Chairman of the Board	less than a year	sin datos	sin datos

5.1yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de 000935700 se considera experimentada (5.1 años de antigüedad promedio).

Gilead Sciences Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Recent updates

Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad